The development of pioneering stimulation therapy for people living with spinal cord injury (SCI) is continuing with ONWARD completing enrolment for its latest groundbreaking trial.
The LIFT Home Study is designed to study the safety and performance of ONWARD’s ARC EX therapy when used in the home.
ARC EX works by externally delivering programmed stimulation of the spinal cord to restore strength and function in people with SCI and other movement related challenges.
It has already been in trial in a medical setting through the Up-LIFT pivotal trial enrolling 65 people internationally ahead of schedule, despite the challenges presented by the COVID-19 pandemic, and is already yielding strong initial results.
Its ARC IM implantable technology is also in trial, with its STIMO-BRIDGE study enabling three long-paralysed patients to regain the ability to take steps independently after one day, and to swim and/or cycle after five months of rehabilitation.
The LIFT Home Study has enrolled 17 participants at five leading research centres in the United States – Craig Hospital in Denver, Colorado; Shepherd Center in Atlanta, Georgia; Spaulding Research Institute in Boston, Massachusetts; University of Minnesota, and University of Washington.
Participants were followed for four weeks to assess whether continued access to ONWARD’s ARC EX therapy is safe and can be used to achieve long-term benefit.
The trial builds further on the commitment of ONWARD, based in Lausanne in Switzerland, to regain function and independence for those living with SCI. Plans remain on track for its ARC EX technology to be commercialised next year.
Dr Candy Tefertiller, executive director of research and evaluation at Denver’s Craig Hospital is primary investigator, and said: “The LIFT Home Study is an important next step in understanding the potential benefits people with spinal cord injury may derive from continued access to ARC Therapy outside the clinic.
“We are pleased enrolment is now complete and we look forward to completing follow-up activities.”
“We are grateful to collaborate with these outstanding researchers to investigate new potential benefits and care settings for our ARC EX therapy,” said Dave Marver, CEO of ONWARD.
“This is another step in our journey to help people with spinal cord injury regain function and independence.”
- Patient story2 weeks ago
Securing a diagnosis – ‘I was relieved but broken’
- Brain injury4 weeks ago
App supports management of concussion symptoms
- Parkinson's2 weeks ago
Kinetikos Health – digital clinical support for Parkinson’s patients
- Insight1 week ago
Nutrition and maximising rehab outcomes in older adults
- Interviews4 days ago
Living with a brain tumour could get a little bit easier
- Interviews1 week ago
Video: “How MS inspired my own Forrest Gump story”
- Research2 weeks ago
Robotics could be the future of stroke surgery
- Insight3 weeks ago
Re:Cognition aims to help thousands of Americans affected by neuro conditions